Gain Therapeutics (GANX) awards director 25,000 options at $1.68
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gain Therapeutics director Jeffrey Scott Riley received a grant of stock options for 25,000 shares of common stock on July 15, 2026. The options have a $1.68 exercise price and expire on July 15, 2036. They vest in 12 equal monthly installments starting July 24, 2026, contingent on his continuous service, resulting in 25,000 options held directly after the grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Riley Jeffrey Scott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options Granted: 25,000 options
Exercise Price: $1.68 per share
Expiration Date: July 15, 2036
+2 more
5 metrics
Options Granted
25,000 options
Stock Option (right to buy) grant to director on July 15, 2026
Exercise Price
$1.68 per share
Exercise price for the 25,000 stock options
Expiration Date
July 15, 2036
Expiration of the granted stock options
Vesting Schedule
12 monthly installments
Vesting commences on July 24, 2026, subject to continuous service
Holdings After Grant
25,000 options
Total stock options held directly following the reported transaction
Key Terms
Stock Option (right to buy), exercise price, vesting, continuous service
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.6800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option vests in 12 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
continuous service financial
"subject to the Reporting Person's continuous service"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Gain Therapeutics (GANX) report about Jeffrey Scott Riley in this Form 4?
Gain Therapeutics reported that director Jeffrey Scott Riley received a grant of 25,000 stock options on July 15, 2026. These options relate to common stock, have a defined exercise price and expiration date, and represent a compensation-related award, not an open-market share purchase.
How many Gain Therapeutics (GANX) options were granted to Jeffrey Scott Riley and at what price?
Jeffrey Scott Riley was granted 25,000 stock options for Gain Therapeutics common stock with an $1.68 exercise price per share. The options were awarded at no cost on the grant date, with value realized only if the market price exceeds the exercise price upon future exercise.
When do Jeffrey Scott Riley’s Gain Therapeutics (GANX) options vest?
The options begin vesting on July 24, 2026 in 12 equal monthly installments. Each month, one-twelfth of the 25,000-option grant becomes exercisable, provided Riley remains in continuous service through each applicable vesting date as specified in the award terms.
What is the expiration date of Jeffrey Scott Riley’s Gain Therapeutics (GANX) stock options?
The stock options granted to Jeffrey Scott Riley expire on July 15, 2036. After this expiration date, any unexercised options from the 25,000-option grant will lapse and can no longer be used to purchase Gain Therapeutics common stock at the stated exercise price.
Was Jeffrey Scott Riley’s Gain Therapeutics (GANX) option grant an open-market transaction?
No. The filing describes the transaction as a grant or award of stock options, not an open-market trade. Riley received 25,000 options at a $1.68 exercise price as part of compensation, with no reported cash purchase of existing Gain Therapeutics shares.
How many Gain Therapeutics (GANX) options does Jeffrey Scott Riley hold after this grant?
Following this reported transaction, Jeffrey Scott Riley directly holds 25,000 stock options linked to Gain Therapeutics common stock. These options vest monthly over 12 installments starting July 24, 2026, and remain exercisable until their stated expiration on July 15, 2036, subject to plan terms.